Can Infigratinib be used if there is no target?

Infigratinib/Infigratinib (Infigratinib) is a therapeutic drug specially designed to target specific molecules. Its main mechanism of action is to inhibit the activity of fibroblast growth factor receptor (FGFR). Therefore, it is primarily used to treat patients with cholangiocarcinoma who have FGFR2 gene abnormalities that are key indications for infigratinib treatment.

If the patient does not have cancer associated with the FGFR2 gene abnormality, infigratinib/infigratinib may not be an appropriate treatment option. For other types of cancer, different targeted therapies may be needed that have mechanisms of action and targets relevant to that specific cancer type.

Therefore, when deciding on a treatment option, patients should first undergo genetic testing to determine whether there are genetic abnormalities relevant to infigratinib/infigratinib treatment. If there is no corresponding genetic abnormality, Infitinib/Infigratinib may not have a significant therapeutic effect. In this case, medical professionals will often explore other treatment options, including radiation, chemotherapy, immunotherapy, or other targeted therapies where applicable.

In short, Infigratinib/Infigratinib is a specific purpose targeted therapy drug, mainly used to treat cholangiocarcinoma related to FGFR2 gene abnormalities. For other cancer types, different treatment options need to be considered because they may involve different targets and drugs. Treatment decisions should be made by a medical professional based on the patient's specific condition and genetic characteristics.

Infigratinib/Infigratinib It is not currently available in the country, and it is unlikely to be included in medical insurance. Patients cannot purchase it domestically and can only purchase it through overseas channels. OverseasInfitinib/InfigratinibThere is only the original drug, only the American original drug, and the price is as high as about 200,000.